Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

PURPOSE: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas that express higher levels of progesterone receptor isoform A (PRA) than isoform B (PRB). Thus, we designed a presurgical window of opportunity trial to determine the therapeutic effects of mifepris...

Descripción completa

Detalles Bibliográficos
Autores principales: Elía, Andrés, Saldain, Leo, Vanzulli, Silvia I., Helguero, Luisa A., Lamb, Caroline A., Fabris, Victoria, Pataccini, Gabriela, Martínez-Vazquez, Paula, Burruchaga, Javier, Caillet-Bois, Ines, Spengler, Eunice, Acosta Haab, Gabriela, Liguori, Marcos, Castets, Alejandra, Lovisi, Silvia, Abascal, María F., Novaro, Virginia, Sánchez, Jana, Muñoz, Javier, Belizán, José M., Abba, Martín C., Gass, Hugo, Rojas, Paola, Lanari, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975668/
https://www.ncbi.nlm.nih.gov/pubmed/36269797
http://dx.doi.org/10.1158/1078-0432.CCR-22-2060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975668/
https://www.ncbi.nlm.nih.gov/pubmed/36269797
http://dx.doi.org/10.1158/1078-0432.CCR-22-2060

Ejemplares similares